US · MIRA
MIRA Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Baltimore, MD 21205
- Website
- mirapharmaceuticals.com
Price · as of 2024-12-31
$1.04
Market cap 53.18M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $1.57 | ||||
| 2024 | $1.01 |
AI valuation
Our deep-learning model estimates MIRA Pharmaceuticals, Inc.'s (MIRA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.04
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MIRA | MIRA Pharmaceuticals, Inc… | $1.04 | 53.18M | — | — | — | — | -1.99 | 7.09 | — | -1.59 | — | 7.09 | 0.00% | — | — | -238.90% | 1872.70% | -199.93% | 0.00 | -48.40 | 3.99 | 3.92 | 0.35 | -2154.00% | — | 2269.00% | -35.65% | -7.69 | 1298.69% | 0.00% | 0.00% | 0.00% | -1.59 | -2.30 | — | -9.18 |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| MODD | Modular Medical, Inc. | $0.25 | 15.64M | — | — | — | — | -1.66 | 1.83 | — | -1.09 | — | 1.83 | 0.00% | — | — | -131.58% | -459.49% | -115.69% | 0.05 | — | 10.69 | 10.41 | 0.71 | -3462.00% | — | 1636.00% | -58.31% | -12.43 | -439.34% | 0.00% | 0.00% | 13.57% | -1.00 | -1.04 | — | 2.40 |
| POCI | Precision Optics Corporat… | $4.28 | 33.04M | +286% | +2,105% | — | — | -5.25 | 2.48 | 1.59 | -5.73 | -7.15 | 9.48 | 17.83% | -29.08% | -30.28% | -51.78% | -43.34% | -31.50% | 0.17 | -24.45 | 1.64 | 0.99 | -0.05 | 7347.00% | -7.00% | 2680.00% | -12.44% | -0.58 | -29.47% | 0.00% | 0.00% | 9.11% | -5.52 | -8.11 | 1.60 | -1.34 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| TLPH | Talphera, Inc. | $0.91 | 18.7M | +3,728% | — | — | — | -1.09 | 1.78 | — | -0.78 | — | 1.78 | 0.00% | — | — | -117.65% | -293.62% | -67.32% | 0.82 | -38.71 | 3.56 | 3.35 | 0.15 | -6124.00% | -10000.00% | -2790.00% | -89.22% | -4.79 | -244.16% | 0.00% | 0.00% | 0.00% | -0.78 | -0.94 | — | -36.58 |
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
- CEO
- Erez Aminov
- Employees
- 2
- Beta
- 1.82
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.04) − 1 = — (DCF, example).